.jpg)
Novartis, a leading Swiss pharmaceutical company, has expressed interest in evaluating India's manufacturing capabilities and technology advancements. The global Chief Executive Officer (CEO) of Novartis, Vas Narasimhan, stated that if the company needs more manufacturing capacity or technology advancements in the future, they would consider Hyderabad, India, as a viable location. Novartis has invested over $300 million in the last five years in India, where the company has a portfolio of both innovative and established medicines in the fields of cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory, and organ transplant.
Narasimhan made the remarks on the sidelines of BioAsia 2023, Telangana's 20th annual flagship life sciences and healthcare event, where he also spoke about India's progress in refining its policies on clinical trials and streamlining intellectual property rights. However, he called for regulatory data protection in India. Narasimhan stated that Novartis is currently conducting over 100 clinical trials involving over 3000-4000 patients in India, and that the new policy allows for a more streamlined approach that speeds up clinical trials.
Novartis has a broad footprint in India, covering early research, drug development, technical operations, business services, and commercial operations, making India one of the few countries in the world with a wide range of Novartis activities. The company has a site in Hyderabad, where it is adopting a technology and data science approach. Novartis is taking a global data science approach and will be led and built by its Hyderabad teams, with a global network. As a company that aspires to be a leader in data science and research and development, Novartis is also exploring the use of generative artificial intelligence (AI) in its R&D.
In conclusion, Novartis is looking to further expand its presence in India, and the CEO's remarks suggest that the country has the potential to become an important location for the company's manufacturing capabilities and technology advancements. Novartis' investment in India over the last five years has been significant, and the company's portfolio in India is diverse, covering a range of medical areas. Novartis' interest in India's data science and technology advancements bodes well for the country's aspirations to become a leader in these areas.
